Novartis Enjoys Solid Product Platform and Growing Pipeline

摘要

With many pharma companies reliant on in-licensing to fill the cracks in a leaky pipeline and revitalize an againg portfolio, Novartis AG has used this strategy to fatten an already solid lineup. The Swiss pharmaceutical major, working with the edge of a firm with a young portfolio and a relatively steady stream of new product launches, has recently made a series of calculated maneuvers to capture promising drugs, in some cases at a substantial discount.